Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
KMDA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.74 - $9.16
Previous CloseN/A
Volume680.22K
Average Volume (3M)111.49K
Market Cap
$382.88M
Enterprise Value$1.03B
Total Cash (Recent Filing)$22.64M
Total Debt (Recent Filing)$25.00M
Price to Earnings (P/E)26.4
Beta0.62
Next Earnings
May 27, 2025EPS Estimate
0.07Last Dividend Ex-Date
Mar 17, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding57,505,030
10 Day Avg. Volume61,719
30 Day Avg. Volume111,487
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.66
Enterprise Value/Ebitda33.92
Forecast
1Y Price Target
$13.00Price Target Upside96.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Kamada News
PremiumCompany Announcements
Kamada Announces Tax Ruling on Special Cash Dividend
PremiumCompany Announcements
Kamada Expands Plasma Collection Operations with New San Antonio Center
---
Bulls Say, Bears Say
Bulls Say
Financial PositionWith a solid cash position and no long-term debt, Kamada is in a good financial position to acquire more products for its portfolio, potentially expanding growth.
Product ExpansionKamada has expanded its specialty plasma-derived product line through acquisitions and organic growth, which is expected to drive double-digit revenue growth and expanding margins.
R&D And TrialsAn active internal R&D pipeline includes a novel AAT Deficiency treatment entering a Phase 3 trial, which could expand the treatment of this under-diagnosed genetic respiratory ailment.
Bears Say
AAT Program ChallengesDespite prior positive guidance from the European Medicines Agency, Kamada has yet to find a partner for the AAT program.
Inhaled AAT ProgramThe stock may rally if the inhaled AAT program is discontinued, as some shareholders view it as a distraction from the company’s core competencies.
Trial Enrollment ChallengesEnrollment in the AAT trial is expected to be a challenge despite additional sites being opened.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.97% Mutual Funds
4.48% Other Institutional Investors
92.32% Public Companies and
Individual Investors
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $4.74 and its highest was $9.15 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $382.88M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is May 27, 2025 which is in 27 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Mar 05, 2025. The company reported $0.073 earnings per share for the quarter, beating the consensus estimate of $0.053 by $0.02.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of $0.199 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.07.
How many shares outstanding does Kamada have?
Kamada has 57,505,030 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.073 in its last earnings report, beating expectations of $0.053. Following the earnings report the stock price went up 7.477%.
Which hedge fund is a major shareholder of Kamada?
Among the largest hedge funds holding Kamada’s share is ARK Investment Management LLC. It holds Kamada’s shares valued at 0.
---
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (96.97% Upside)
$13.00 (96.97% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.60%
12-Months-Change
Fundamentals
Return on Equity
5.74%
Trailing 12-Months
Asset Growth
4.89%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
---
KMDA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Kamada delivered strong financial performance in 2024 with record revenues and adjusted EBITDA, supported by successful product launches and expansion of plasma collection centers. However, increased operating expenses and financial challenges in Q4 2024 were noted. The company's positive outlook for 2025, including expected revenue and EBITDA growth, and the declaration of a special dividend, indicate confidence in future performance.Read More>---
KMDA Stock 12 Month Forecast
Average Price Target
$13.00
▲(96.97% Upside)
Technical Analysis
---